Search

Your search keyword '"Tezuka, Shun"' showing total 44 results
Start Over Author "Tezuka, Shun"
44 results on '"Tezuka, Shun"'

1. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407

Author

Tezuka, Shun, Ozaka, Masato, Furuse, Junji, Yokoyama, Masayuki, Uemura, Kohei, Sano, Yusuke, Nakachi, Kohei, Imaoka, Hiroshi, Unno, Michiaki, Shirakawa, Hirofumi, Shimizu, Satoshi, Kato, Naoya, Kojima, Yasushi, Sano, Keiji, Kobayashi, Satoshi, Terashima, Takeshi, Morizane, Chigusa, Ikeda, Masafumi, and Ueno, Makoto

Published
2024
Full Text
View/download PDF

9. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer

Author

Kobayashi, Satoshi, Ueno, Makoto, Ikeda, Masafumi, Ozaka, Masato, Sano, Yusuke, Hirotani, Akane, Tozuka, Yuichiro, Fukushima, Taito, Tezuka, Shun, Moriya, Satoshi, Umemoto, Kumiko, Watanabe, Kazuo, Sasaki, Mitsuhito, Hashimoto, Yusuke, Imaoka, Hiroshi, Ohno, Izumi, Mitsunaga, Shuichi, Yamada, Ikuhiro, Sasaki, Takashi, Sasahira, Naoki, and Morimoto, Manabu

Published
2020
Full Text
View/download PDF

11. Early tumor shrinkage as a predictor of survival in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.

Author

Tezuka, Shun, primary, Ozaka, Masato, additional, Furuse, Junji, additional, Uemura, Kohei, additional, Sano, Yusuke, additional, Nakachi, Kohei, additional, Imaoka, Hiroshi, additional, Unno, Michiaki, additional, Shirakawa, Hirofumi, additional, Shimizu, Satoshi, additional, Kato, Naoya, additional, Kojima, Yasushi, additional, Sano, Keiji, additional, and Ueno, Makoto, additional

Published
2023
Full Text
View/download PDF

12. Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.

Author

Tezuka, Shun, primary, Sakai, Shunsuke, additional, Yamashita, Riu, additional, Horasawa, Satoshi, additional, Fujisawa, Takao, additional, Sawada, Kentaro, additional, Yoshikawa, Ayumu, additional, Nakamura, Yoshiaki, additional, Umemoto, Kumiko, additional, Shibata, Nobuhiro, additional, Ohtsubo, Koushiro, additional, Itoh, Shinji, additional, Todaka, Akiko, additional, Sudo, Kentaro, additional, Furukawa, Masayuki, additional, Ikeda, Masafumi, additional, Morizane, Chigusa, additional, Ueno, Makoto, additional, and Yoshino, Takayuki, additional

Published
2023
Full Text
View/download PDF

13. Clinical therapeutic effects of neoadjuvant chemotherapy in resectable pancreatic cancer.

Author

Murakawa, Masaaki, primary, Takahashi, Daishi, additional, Kawahara, Shinnosuke, additional, Kamioka, Yuto, additional, Yamamoto, Naoto, additional, Tezuka, Shun, additional, Kobayashi, Satoshi, additional, Ueno, Makoto, additional, Morimoto, Manabu, additional, Oshima, Takashi, additional, Yukawa, Norio, additional, Rino, Yasushi, additional, and Morinaga, Soichiro, additional

Published
2023
Full Text
View/download PDF

15. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: A retrospective observational study

Author

Kobayashi, Satoshi, primary, Tezuka, Shun, additional, Yamachika, Yui, additional, Tsunoda, Shotaro, additional, Nagashima, Shuhei, additional, Tozuka, Yuichiro, additional, Fukushima, Taito, additional, Morimoto, Manabu, additional, Ueno, Makoto, additional, Furuse, Junji, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

16. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study

Author

Tozuka, Yuichiro, primary, Ueno, Makoto, additional, Kobayashi, Satoshi, additional, Morimoto, Manabu, additional, Fukushima, Taito, additional, Sano, Yusuke, additional, Kawano, Kuniyuki, additional, Hanaoka, Akane, additional, Tezuka, Shun, additional, Asama, Hiroyuki, additional, Moriya, Satoshi, additional, Morinaga, Soichiro, additional, Ohkawa, Shinichi, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

18. Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers

Author

Osaki, Takako, primary, Lin, Yingsong, additional, Sasahira, Naoki, additional, Ueno, Makoto, additional, Yonezawa, Hideo, additional, Hojo, Fuhito, additional, Okuda, Masumi, additional, Matsuyama, Masato, additional, Sasaki, Takashi, additional, Kobayashi, Satoshi, additional, Tezuka, Shun, additional, Tanaka, Kei, additional, Dan, Naoaki, additional, Kuruma, Sawako, additional, Egawa, Naoto, additional, Kamiya, Shigeru, additional, and Kikuchi, Shogo, additional

Published
2022
Full Text
View/download PDF

19. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis

Author

Tezuka, Shun, primary, Ueno, Makoto, additional, Oishi, Ritsuko, additional, Nagashima, Shuhei, additional, Sano, Yusuke, additional, Kawano, Kuniyuki, additional, Tanaka, Satoshi, additional, Fukushima, Taito, additional, Asama, Hiroyuki, additional, Konno, Naoki, additional, Kobayashi, Satoshi, additional, Morimoto, Manabu, additional, and Maeda, Shin, additional

Published
2021
Full Text
View/download PDF

20. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Author

Chuma, Makoto, primary, Uojima, Haruki, additional, Hattori, Nobuhiro, additional, Arase, Yoshitaka, additional, Fukushima, Taito, additional, Hirose, Shunji, additional, Kobayashi, Satoshi, additional, Ueno, Makoto, additional, Tezuka, Shun, additional, Iwasaki, Shuichiro, additional, Wada, Naohisa, additional, Kubota, Kousuke, additional, Tsuruya, Kota, additional, Shimma, Yoshimasa, additional, Hiroki, Ikeda, additional, Takuya, Ehira, additional, Tokoro, Chikako, additional, Iwase, Shigeru, additional, Miura, Yuki, additional, Moriya, Satoshi, additional, Watanabe, Tsunamasa, additional, Hidaka, Hisashi, additional, Morimoto, Manabu, additional, Numata, Kazushi, additional, Kusano, Chika, additional, Kagawa, Tatehiro, additional, and Maeda, Shin, additional

Published
2021
Full Text
View/download PDF

21. Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

Author

Kobayashi, Satoshi, primary, Koizume, Shiro, additional, Takahashi, Tomoko, additional, Ueno, Makoto, additional, Oishi, Ritsuko, additional, Nagashima, Shuhei, additional, Sano, Yusuke, additional, Fukushima, Taito, additional, Tezuka, Shun, additional, Morimoto, Manabu, additional, Nakamura, Sho, additional, Narimatsu, Hiroto, additional, Ruf, Wolfram, additional, and Miyagi, Yohei, additional

Published
2021
Full Text
View/download PDF

23. Additional file 3 of Association between time to stent dysfunction and the anti-tumour effect of systemic chemotherapy following stent placement in patients with pancreaticobiliary cancers and malignant gastric outlet obstruction: a retrospective cohort study

Author

Kobayashi, Satoshi, Ueno, Makoto, Nagashima, Shuhei, Sano, Yusuke, Kuniyuki Kawano, Fukushima, Taito, Asama, Hiroyuki, Tezuka, Shun, and Morimoto, Manabu

Subjects
equipment and supplies
Abstract

Additional file 3: Supplement Table 1. The regimens administered after duodenal stenting and the indication of treatment lines.

Published
2021
Full Text
View/download PDF

25. Association Between Time to Stent Dysfunction and the Anti-Tumour Effect of Systemic Chemotherapy Following Stent Placement in Patients With Pancreaticobiliary Cancers and Malignant Gastric Outlet Obstruction: A Retrospective Cohort Study

Author

Kobayashi, Satoshi, primary, Ueno, Makoto, additional, Nagashima, Shuhei, additional, Sano, Yusuke, additional, Kawano, Kuniyuki, additional, Fukushima, Taito, additional, Asama, Hiroyuki, additional, Tezuka, Shun, additional, and Morimoto, Manabu, additional

Published
2021
Full Text
View/download PDF

27. Clinical outcome of a highly flexible duodenal stent for gastric outlet obstruction: A multicenter prospective study

Author

Miwa, Haruo, primary, Sugimori, Kazuya, additional, Kaneko, Takashi, additional, Ishii, Tomohiro, additional, Iwase, Shigeru, additional, Irie, Kuniyasu, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Hirotani, Akane, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Numata, Kazushi, additional, and Maeda, Shin, additional

Published
2020
Full Text
View/download PDF

29. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.

Author

Chuma, Makoto, Uojima, Haruki, Hattori, Nobuhiro, Arase, Yoshitaka, Fukushima, Taito, Hirose, Shunji, Kobayashi, Satoshi, Ueno, Makoto, Tezuka, Shun, Iwasaki, Shuichiro, Wada, Naohisa, Kubota, Kousuke, Tsuruya, Kota, Shimma, Yoshimasa, Hiroki, Ikeda, Takuya, Ehira, Tokoro, Chikako, Iwase, Shigeru, Miura, Yuki, and Moriya, Satoshi

Subjects
HEPATOCELLULAR carcinoma, ATEZOLIZUMAB, BEVACIZUMAB, NEUTROPHIL lymphocyte ratio, SAFETY factor in engineering
Abstract

Purpose: To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u‐HCC). Method: Ninety‐four u‐HCC patients who were treated with ATZ + BV at multiple centers were enrolled. We defined Child‐Pugh (CP)‐A patients who received ATZ + BV treatment as a first line therapy as the 'meets the broad sense of the IMbrave150 criteria' group (B‐IMbrave150‐in, n = 46), and patients who received ATZ + BV treatment as a later line therapy or CP‐B patients (regardless of whether ATZ + BV was a first line or later line therapy) as the B‐IMbrave150‐out group (n = 48). Patients were retrospectively analyzed for adverse events (AEs) and treatment outcomes according to their clinical characteristics, including neutrophil lymphocyte ratio (NLR) at baseline. Results: The overall incidence of AEs was 87.2% (82/94 patients). The frequency of interruption of ATZ + BV treatment due to fatigue was higher in CP‐B than CP‐A patients (p = 0.030). Objective response (OR) rates of the B‐IMbrave150‐in group (28.3%, 39.1%) were significantly higher than those of the B‐IMbrave150‐out group (8.3%, 18.8%; p = 0.0157, 0.0401) using Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST, respectively. In multivariate analysis, NLR (hazard ratio (HR), 4.591; p = 0.0160) and B‐IMbrave150 criteria (HR, 4.108; p = 0.0261) were independent factors associated with the OR of ATZ + BV treatment using RECIST. Conclusion: In real‐world practice, ATZ + BV treatment might offer significant benefits in patients who meet B‐IMbrave150 criteria or have low NLR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy

Author

Sugimori, Makoto, primary, Sugimori, Kazuya, additional, Tsuchiya, Hiromi, additional, Suzuki, Yoshimasa, additional, Tsuyuki, Sho, additional, Kaneta, Yoshihiro, additional, Hirotani, Akane, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Irie, Kuniyasu, additional, Miwa, Haruo, additional, Miura, Yuuki, additional, Ishii, Tomohiro, additional, Kaneko, Takashi, additional, Nagahama, Masatsugu, additional, Shibata, Wataru, additional, Nozaki, Akito, additional, and Maeda, Shin, additional

Published
2019
Full Text
View/download PDF

31. Tu1072 CLINICAL OUTCOME OF HIGHLY FLEXIBLE DUODENAL STENT FOR GASTRIC OUTLET OBSTRUCTION: MULTICENTER PROSPECTIVE STUDY

Author

Miwa, Haruo, primary, Sugimori, Kazuya, additional, Kaneko, Takashi, additional, Ishii, Tomohiro, additional, Iwase, Shigeru, additional, Irie, Kuniyasu, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Hirotani, Akane, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Numata, Kazushi, additional, and Maeda, Shin, additional

Published
2019
Full Text
View/download PDF

32. Su1060 – Clinical Utility of the Quantitative Monitoring of Circulating Tumor Dna in Patients with Advanced Pdac Undergoing Chemotherapy

Author

Sugimori, Makoto, primary, Sugimori, Kazuya, additional, Jimbo, Chiaya, additional, Tsuyuki, Sho, additional, Kaneta, Yoshihiro, additional, Hirotani, Akane, additional, Sanga, Katsuyuki, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Irie, Kuniyasu, additional, Miwa, Haruo, additional, Miura, Yuuki, additional, Ishii, Tomohiro, additional, Shibata, Wataru, additional, Nozaki, Akito, additional, and Maeda, Shin, additional

Published
2019
Full Text
View/download PDF

33. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.

Author

Sugimori, Makoto, Sugimori, Kazuya, Tsuchiya, Hiromi, Suzuki, Yoshimasa, Tsuyuki, Sho, Kaneta, Yoshihiro, Hirotani, Akane, Sanga, Katsuyuki, Tozuka, Yuichiro, Komiyama, Satoshi, Sato, Takeshi, Tezuka, Shun, Goda, Yoshihiro, Irie, Kuniyasu, Miwa, Haruo, Miura, Yuuki, Ishii, Tomohiro, Kaneko, Takashi, Nagahama, Masatsugu, and Shibata, Wataru

Abstract

According to cancer genome sequences, more than 90% of cases of pancreatic ductal adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables accurate detection and quantification of rare mutations. We assessed the dynamics of circulating tumor DNA (ct‐DNA) in patients with advanced PDAC undergoing chemotherapy using dPCR. KRAS G12/13 mutation was assayed by dPCR in 47 paired tissue‐ and ct‐DNA samples. The 21 patients were subjected to quantitative ct‐DNA monitoring at 4 to 8‐week intervals during chemotherapy. KRAS mutation was detected in 45 of those 47 patients using tissue DNA. In the KRAS mutation‐negative cases, next‐generation sequencing revealed KRAS Q61K and NRAS Q61R mutations. KRAS mutation was detected in 23/45 cases using ct‐DNA (liver or lung metastasis, 18/19; mutation allele frequency [MAF], 0.1%‐31.7%; peritoneal metastasis, 3/9 [0.1%], locally advanced, 2/17 [0.1%‐0.2%]). In the ct‐DNA monitoring, the MAF value changed in concordance with the disease state. In the 6 locally advanced cases, KRAS mutation appeared concurrently with liver metastasis. Among the 6 cases with liver metastasis, KRAS mutation disappeared during the duration of stable disease or a partial response, and reappeared at the time of progressive disease. The median progression‐free survival was longer in cases in which KRAS mutation disappeared after an initial course of chemotherapy than in those in which it was continuously detected (248.5 vs 50 days, P <.001). Therefore, ct‐DNA monitoring enables continuous assessment of disease state and could have prognostic utility during chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Erratum To: Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization

Author

Morimoto, Manabu, primary, Kobayashi, Satoshi, additional, Moriya, Satoshi, additional, Ueno, Makoto, additional, Tezuka, Shun, additional, Irie, Kuniyasu, additional, Goda, Yoshihiro, additional, and Ohkawa, Shinichi, additional

Published
2016
Full Text
View/download PDF

40. Sa1528 Endoscopic Duodenal Stenting Followed by Systemic Chemotherapy: Management and Survival Impact on Advanced Pancreatic Cancer With Gastric Outlet Obstruction

Author

Tezuka, Shun, primary, Kobayashi, Satoshi, additional, Ueno, Makoto, additional, Moriya, Satoshi, additional, Irie, Kuniyasu, additional, Goda, Yasuhiro, additional, Ohkawa, Shinichi, additional, Aoyama, Toru, additional, Morinaga, Soichiro, additional, Morimoto, Manabu, additional, and Maeda, Shin, additional

Published
2016
Full Text
View/download PDF

41. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer

Author

Kobayashi, Satoshi, primary, Ueno, Makoto, additional, Hara, Hiroki, additional, Irie, Kuniyasu, additional, Goda, Yoshihiro, additional, Moriya, Satoshi, additional, Tezuka, Shun, additional, Tanaka, Masao, additional, Okusaka, Takuji, additional, Ohkawa, Shinichi, additional, and Morimoto, Manabu, additional

Published
2016
Full Text
View/download PDF

43. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.

Author

Tezuka S, Ueno M, Oishi R, Nagashima S, Sano Y, Kawano K, Tanaka S, Fukushima T, Asama H, Konno N, Kobayashi S, Morimoto M, and Maeda S

Subjects
Fluorouracil adverse effects, Humans, Irinotecan, Leucovorin adverse effects, Oxaliplatin, Retrospective Studies, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols adverse effects, Pancreatic Neoplasms
Abstract

Background: Although second-line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen. This study compared the efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) and sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer., Method: This was a retrospective single-center analysis of all patients who initiated treatment with mFOLFIRINOX or sequential chemotherapy from December 2014 to May 2019 as a second-line treatment for unresectable pancreatic cancer. The sequential chemotherapy group included all patients who initiated sequential chemotherapy. For efficacy analysis, the primary endpoint was overall survival (OS) of all patients, excluding those with locally advanced pancreatic cancer. For safety analysis, we assessed the incidence of grade ≥3 adverse events in all patients., Results: Seventy-four patients (mFOLFIRINOX group, n = 44; sequential chemotherapy group, n = 30) were included. OS tended to be slightly prolonged in the mFOLFIRINOX group than in the sequential chemotherapy group (median 10.6 [95% confidence interval {CI} 5.9-13.8] vs. 8.5 [95% CI 5.0-12.2] months; hazard ratio 1.40 [95% CI 0.71-2.71]). The objective response rate and disease control rate were 8.1% and 64.9%, respectively, in the mFOLFIRINOX group and 3.8% and 42.3%, respectively, in the sequential chemotherapy group. In safety analysis, the grade ≥3 rates of neutropenia, febrile neutropenia, and anorexia were 40.9%, 6.8%, and 18.2%, respectively, in the mFOLFIRINOX group and 3.3%, 0%, and 3.3%, respectively, in the sequential chemotherapy group., Conclusions: Whereas efficacy tended to be slightly better in the mFOLFIRINOX group than in the sequential chemotherapy group, given the higher incidence of grade ≥3 adverse events with mFOLFIRINOX than with sequential chemotherapy, sequential chemotherapy is a regimen with better risk-benefit balance than mFOLFIRINOX, and can be considered a second-line treatment option for patients with unresectable pancreatic cancer., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

44. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.

Author

Tezuka S, Ueno M, Kobayashi S, Morimoto M, Ohkawa S, Hirotani A, Tozuka Y, Moriya S, Nakamura Y, Miyagi Y, Sugimori M, and Maeda S

Abstract

The platinum-based chemotherapy regimen FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) is currently used as a standard treatment for patients with unresectable pancreatic cancer. FOLFIRINOX is associated with severe toxicities, including neutropenia, febrile neutropenia, and anorexia; however, there are currently no reliable biomarkers to predict its efficacy and safety. Several studies of patients with various cancers have shown that tumor expression of excision repair cross-complementing (ERCC) proteins and glutathione S-transferase Pi (GSTPi) correlates with the response to platinum-based chemotherapies. Therefore, in this study, we examined the associations between expression of ERCC proteins and GSTPi and the safety and efficacy of FOLFIRINOX in 34 patients with unresectable pancreatic cancer. ERCC1, ERCC2, ERCC4, and GSTPi expression were examined by immunohistochemical staining of tumor specimens and the results were correlated with overall survival, progression-free survival, response rate, disease control rate, and the frequency of grade 3-4 neutropenia and non-hematologic toxicities. We found that ERCC1, ERCC2, ERCC4, and GSTPi were expressed in tumor samples from 64%, 24%, 18%, and 64% of patients, respectively. Notably, there were no statistically significant associations between the expression pattern of any of the proteins and either the clinical outcomes or the frequency of grade 3-4 neutropenia or grade 3-4 anorexia. Collectively, these data indicate that tumor expression of ERCC1, ERCC2, ERCC4, and GSTPi does not predict the safety or efficacy of FOLFIRINOX in patients with pancreatic cancer., Competing Interests: None.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results